Rheos Medicines appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business Development – Natural Self Esteem

The Company is expanding the management team with seasoned industry leaders as it advances the precision medicine pipeline for autoimmune diseases

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rheos Medicines, Inc., a biopharmaceutical company providing molecular targeting and precise treatments for autoimmune and inflammatory diseases, today announced the appointment of Katerina Leftheris, Ph.D., to Senior Vice President of Drug Discovery and Nabil Uddin, Pharm.D., as Vice President of Strategy and Business Development.

“We are excited to add these two accomplished industry leaders to the Rheos leadership team and to deepen our expertise in key areas of our science and business to support our future growth,” said Barbara Fox, Ph.D., Chief Executive Officer of Rheos. “Katerina brings to the clinic extensive experience in small molecule drug discovery and a successful track record of advancing drug candidates across a range of therapeutic areas. Nabil’s diverse expertise in strategy, operations and business development roles in the biopharmaceutical industry and his proven ability to strategize in new market areas will be invaluable as Rheos advances our pipeline opportunities.”

Katerina Leftheris, Ph.D., Senior Vice President, Drug Discovery

“I look forward to using my experience to help advance Rheos’ pipeline to develop precision medicines for autoimmune and inflammatory diseases,” said Dr. leftheris. “I see tremendous potential for the company’s pioneering approach to address fundamental metabolic bases of immune system disorders while simultaneously identifying the molecular signatures for subsets of patients. It is exciting to be part of a new drug development paradigm at Rheos to address the heterogeneity of immune-mediated diseases and address the vast unmet needs of patients.”

Katerina Leftheris, Ph.D., brings over 20 years of experience in small molecule drug discovery and development, including multiple compounds in phase 1, 2 and 3 targeting immunomodulation, fibrosis, oncology and immuno-oncology indications. Throughout her career, she has led teams that have advanced more than 15 small molecule drugs into clinical development, spanning multiple molecular targets. Most recently, she was Vice President of Chemistry at Pliant Therapeutics, a biotech company focused on novel treatments for fibrotic diseases. Katerina helped build Pliant’s drug discovery capabilities, resulting in two drugs in the clinic (one in partnership with Novartis) to treat idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC) and NASH with a third compound focused on immuno-oncology focuses on early development. Previously, Katerina was Senior Director in Discovery at Celgene, San Diego, where she built and led teams advancing five novel clinical candidates in the areas of immunology and oncology. Earlier in her career, she held R&D positions at Vitae Pharmaceuticals and in Bristol-Myers Squibb’s Discovery Oncology and Immunology Chemistry group. Katerina was elected to the National Council of the American Chemical Society and has authored over 135 publications and issued patents. She earned a BA in Chemistry/Biochemistry from Smith College, a Ph.D. in organic chemistry from the University of California, San Diego and completed postdoctoral studies at the University of Pennsylvania.

Nabil Uddin, Pharm.D., Vice President, Strategy & Business Development

“This is an exciting time to join Rheos as the company advances its precision medicine approach to autoimmune and inflammatory diseases, brings its first drug candidate to the clinic and advances its pipeline,” said Dr. uddin “I am committed to using my experience to support the growth of the company and I look forward to working with the talented Rheos team to achieve our shared goals and mission of improving the lives of patients across many diseases .”

Nabil Uddin, Pharm.D., comes to Rheos with over 15 years of experience in strategic and operational roles, including program and alliance management, portfolio planning, corporate strategy and business development. Most recently, he served as vice president, corporate development at Concert Pharmaceuticals, where he was responsible for corporate strategy, business development, program management and commercial planning. Nabil joined Concert to provide strategic and operational leadership for a program in cystic fibrosis that was eventually acquired by Vertex Pharmaceuticals. Prior to Concert, Nabil worked at Seaside Therapeutics, a company focused on neurodevelopmental disorders such as Fragile X Syndrome and Autism Spectrum Disorders. Earlier in his career, he worked as a strategic planning and program management consultant. Nabil earned a B.Sc. in Biology from McMaster University, a Pharm.D. from Massachusetts College of Pharmacy and completed a postdoctoral fellowship at the University of North Carolina at Chapel Hill.

About Rheos medication
Rheos Medicines is a biopharmaceutical company developing precision medicines to treat autoimmune and inflammatory diseases by identifying and targeting the molecular characteristics and patient subsets of these complex diseases. Using our proprietary MetPM™ platform, the Rheos team integrates an unmatched knowledge base of immunometabolism networks based on bioinformatic integration of genetic, transcriptomic, epigenomic and metabolomic datasets, including patient data and samples. We have built a pipeline of novel, differentiated drug programs to address autoimmune and inflammatory diseases by targeting the fundamental fundamentals of immune system dysfunction while identifying the molecular signatures for patient stratification and selection. Rheos has assembled leading scientists whose discoveries opened up the field of immune metabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is based in Cambridge, MA. Visit www.rheosrx.com/ for more information. We invite you to follow us on LinkedIn and @Rheosrx.

Leave a Comment